Medgenics is engaged in developing and commercializing Biopump, a novel technology for the sustained production and delivery of therapeutic proteins utilizing patients’ own skin biopsies. Biopump is designed to treat various chronic diseases, including anemia, hepatitis C and hemophilia. Based on this technology, the company is currently developing three long-acting protein therapy products: EPODURE, INFRADURE, and HEMODURE. Medgenics additionally has a pipeline of other Biopump products in view. For more information visit the company’s Web site at www.medgenics.com

ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year’s annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 11-14. Bringing together executives from more than 400 growth companies, the 24th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit www.roth.com

Let us hear your thoughts below: